Shares of Natco Pharma slipped 6 per cent to Rs 1,092.35 on the BSE in intra-day trade on Wednesday after the Delhi High Court allowed the application by FMC Corporation on Chlorantraniliprole (CTPR).
The generic drug maker was engaged in a legal battle with California-based agriculture sciences company FMC over the use of an insecticide CTPR that is used in several crops.
“The Hon'ble High Court of Delhi has today orally pronounced judgment in the interim injunction application filed by FMC Corporation on CTPR. The Hon'ble Court said that it has allowed the application of FMC Corporation,” Natco Pharma said in an